Dermata Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the year endedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $8,203,691 | $4,069,766 |
| General and administrative | 4,309,551 | 3,972,140 |
| Total operating expenses | 12,513,242 | 8,041,906 |
| Loss from operations | (12,513,242) | (8,041,906) |
| Other income and expenses: | ||
| Interest income | 225,781 | 247,216 |
| Net loss | $(12,287,461) | $(7,794,690) |
| Net loss per share of common stock, basic and diluted | $(8.03) | $(39.99) |
| Weighted-average basic and diluted common shares | 1,529,772 | 194,928 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.